Zoetis Inc. ZTS
At closeNov 6, 2026, 7:55 PM EST
After hours · Nov 6, 7:55 PM ET
- YTD
- -36.89%
- 1 year
- -33.59%
- Market cap
- 32.81B
- Revenue (ttm)
- 9.52B
- Profit margin
- 26.35%
- EPS (ttm)
- 5.88
- Shares out
- 413.22M
- P/E ratio
- 13.50
- Forward P/E
- 12.40
- Dividend
- 2.12 (2.58%)
- Ex-dividend date
- Oct 29, 2026
- YTD return
- -36.89%
- 1-year return
- -33.59%
- Volume
- 6.02M
- Avg volume
- 4.79M
- Open
- 79.00
- Previous close
- 82.11
- Day's range
- 78.66 – 80.67
- 52-week range
- 69.10 – 131.10
- Analysts
- Hold
- Price target
- 88.38 (+11.3%)
- Earnings date
- Feb 11, 2027
5D -1.62 (-2.00%)
Key statistics
- Enterprise value
- 41.16B
- PEG ratio
- 15.28
- Price / sales
- 3.45
- Price / book
- 9.80
- Dividend yield
- 2.58%
- Payout ratio
- 35.24%
- Revenue growth
- -0.40%
- Free cash flow
- 1.96B
- Total cash
- 1.53B
- Total debt
- 9.24B
- Return on equity
- 57.63%
- Short % of float
- 4.80%
- 50-day average
- 75.60
- 200-day average
- 92.72
Analyst view
Consensus: hold
- Target (low)
- 74.00
- Target (mean)
- 88.38
- Target (high)
- 115.00
- Strong buy3
- Buy2
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 11, 2027
Expected Feb 11, 2027. Consensus EPS estimate 1.31.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2027 | Dec 30, 2026 | 1.29 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 1.51 | 1.75 | +0.24 | +15.89% |
| Aug 6, 2026 | Jun 30, 2026 | 1.85 | 1.87 | +0.02 | +1.08% |
| May 7, 2026 | Mar 31, 2026 | 1.60 | 1.53 | -0.07 | -4.38% |
| Feb 12, 2026 | Dec 31, 2025 | 1.40 | 1.48 | +0.08 | +5.71% |
| Nov 4, 2025 | Sep 30, 2025 | 1.62 | 1.70 | +0.08 | +4.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 27, 2026 | UBS | main | Neutral | Neutral |
| Oct 20, 2026 | Jefferies | down | Buy | Hold |
| Oct 16, 2026 | Goldman Sachs | init | — | Neutral |
| Aug 25, 2026 | TD Cowen | main | Buy | Buy |
| Aug 20, 2026 | Stifel | main | Hold | Hold |
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- zoetis.com
News
Republican Senator Who Won Reelection Is Selling Magnificent Seven Stocks: Here Are the Trades
Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
Zoetis (ZTS) Reports Q3 Earnings: What Key Metrics Have to Say
Zoetis Q3 2026 Earnings Call Transcript
Zoetis (ZTS) Q3 Earnings and Revenues Top Estimates Zoetis Raises FY2026 Adj EPS Guidance from $6.15-$6.25 to $6.25-$6.35 vs $6.28 Est; Raises FY2026 Sales Guidance from $9.120B-$9.320B to $9.220B-$9.320B vs $9.326B Est
Zoetis Q3 Adj. EPS $1.75 Beats $1.51 Estimate, Sales $2.391B Beat $2.304B Estimate
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
Zoetis: Near-Term Expectations More Achievable, Long Growth Runway Undervalued
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
Your note
Sign in to keep a note on ZTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BISARO PAUL M. | Director | Purchase | May 12, 2026 | 27,862 |
| D AMELIO FRANK A | Director | Stock Gift | Aug 6, 2026 | 21,458 |
| JOSEPH WETTENY | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 5, 2026 | 20,766 |
| LAGANO ROXANNE | Officer | Conversion of Exercise of derivative security | Feb 18, 2026 | 16,465 |
| MCCALLISTER MICHAEL B | Director | Stock Gift | Jun 9, 2026 | 31,893 |
| NORDEN GREGORY | Director | Stock Gift | Mar 8, 2026 | 18,167 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.54% | 39,430,181 | 3.13B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.30% | 26,027,984 | 2.07B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.77% | 23,860,445 | 1.90B | Jun 29, 2026 |
| State Street Corporation | 4.76% | 19,667,723 | 1.56B | Jun 29, 2026 |
| State Farm Mutual Automobile Insurance Co | 3.85% | 15,892,903 | 1.26B | Jun 29, 2026 |
| Geode Capital Management, LLC | 3.22% | 13,289,622 | 1.06B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 11,982,269 | 951.75M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.63% | 10,862,724 | 862.83M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 1.98% | 8,175,936 | 649.41M | Jun 29, 2026 |
| VANGUARD FENWAY FUNDS-Vanguard Equity Income Fund | 1.48% | 6,106,220 | 485.02M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 5,506,516 | 437.38M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 5,370,257 | 426.56M | Sep 29, 2026 |
